×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APTO – aptose biosciences, inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APTO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
03:06 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/20
01:16 pm
apto
Aptose Biosciences Inc. (NASDAQ: APTO) had its price target lowered by analysts at HC Wainwright from $7.00 to $2.00. They now have a "buy" rating on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) had its price target lowered by analysts at HC Wainwright from $7.00 to $2.00. They now have a "buy" rating on the stock.
11/20
07:39 am
apto
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy [Yahoo! Finance]
High
Report
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy [Yahoo! Finance]
11/20
07:30 am
apto
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
High
Report
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
11/13
03:01 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/8
05:28 pm
apto
Aptose Reports Results for the Third Quarter 2024 [Canadian Business Journal (Canada)]
Low
Report
Aptose Reports Results for the Third Quarter 2024 [Canadian Business Journal (Canada)]
11/8
04:01 pm
apto
Aptose Reports Results for the Third Quarter 2024
Low
Report
Aptose Reports Results for the Third Quarter 2024
11/5
02:13 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
08:01 am
apto
Form 8-K Aptose Biosciences Inc. For: Nov 20
High
Report
Form 8-K Aptose Biosciences Inc. For: Nov 20
11/14
03:22 pm
apto
Form SC 13G Aptose Biosciences Inc. Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G Aptose Biosciences Inc. Filed by: ARMISTICE CAPITAL, LLC
11/12
09:20 am
apto
Form 10-Q Aptose Biosciences Inc. For: Sep 30
Low
Report
Form 10-Q Aptose Biosciences Inc. For: Sep 30
11/8
04:03 pm
apto
Form 8-K Aptose Biosciences Inc. For: Nov 08
Low
Report
Form 8-K Aptose Biosciences Inc. For: Nov 08
10/31
06:40 am
apto
Form S-1/A Aptose Biosciences Inc.
Low
Report
Form S-1/A Aptose Biosciences Inc.
10/4
04:16 pm
apto
Form 8-K Aptose Biosciences Inc. For: Oct 01
Medium
Report
Form 8-K Aptose Biosciences Inc. For: Oct 01
9/6
04:15 pm
apto
Form 8-K Aptose Biosciences Inc. For: Sep 05
Low
Report
Form 8-K Aptose Biosciences Inc. For: Sep 05
9/5
04:26 pm
apto
Form 8-K Aptose Biosciences Inc. For: Sep 05
Medium
Report
Form 8-K Aptose Biosciences Inc. For: Sep 05
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/7
Aptose Presents Highlights From Corporate Event At ASH
35.1%
3/12 Form 4 Aptose Biosciences Inc. For: Mar 10 Filed by: Chow Gregory K. 20.7%
1/9 Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $10.00 price target on the stock. 10.0%
5/30 Aptose Announces Pricing of Public Offering of Common Shares 9.9%
12/18 Form 424B5 Aptose Biosciences Inc. 9.3%
5/29 Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at Roth Capital. 8.7%
10/22 Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019 8.5%
4/14 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.50 price target on the stock. 8.0%
3/16 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock. 7.6%
1/29 Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference 7.2%
3/12 Form 4 Aptose Biosciences Inc. For: Mar 10 Filed by: Chow Gregory K. 20.7%
1/9 Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $10.00 price target on the stock. 10.0%
5/30 Aptose Announces Pricing of Public Offering of Common Shares 9.9%
12/18 Form 424B5 Aptose Biosciences Inc. 9.3%
5/29 Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at Roth Capital. 8.7%
10/22 Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019 8.5%
4/14 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.50 price target on the stock. 8.0%
3/16 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock. 7.6%
1/29 Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference 7.2%
TOP News Decliners
3/10
Form 10-K Aptose Biosciences Inc. For: Dec 31
-21.6%
3/12 Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -18.3%
4/27 Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020 -12.6%
12/17 Aptose up 3% after pricing stock offering [Seeking Alpha] -11.7%
8/6 Form 8-K Aptose Biosciences Inc. For: Aug 06 -9.7%
4/29 Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.3%
3/13 Form 4 Aptose Biosciences Inc. For: Mar 11 Filed by: PLATZER ERICH -8.8%
5/29 Aptose Announces Proposed Public Offering of Common Shares -7.4%
12/24 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.3%
9/16 Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies -7.2%
3/12 Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -18.3%
4/27 Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020 -12.6%
12/17 Aptose up 3% after pricing stock offering [Seeking Alpha] -11.7%
8/6 Form 8-K Aptose Biosciences Inc. For: Aug 06 -9.7%
4/29 Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.3%
3/13 Form 4 Aptose Biosciences Inc. For: Mar 11 Filed by: PLATZER ERICH -8.8%
5/29 Aptose Announces Proposed Public Offering of Common Shares -7.4%
12/24 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.3%
9/16 Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies -7.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: